Results 291 to 300 of about 1,375,213 (331)

Efficacy of IL-23 inhibitors in axial involvements of chronic non-bacterial osteitis with palmoplantar pustulosis: a case series. [PDF]

Rheumatology (Oxford)
Yamamoto H, Taniguchi Y, Tsuji S, Helliwell PS, Kishimoto M.   +4 more
europepmc   +1 more source

LDAcoop: Integrating non‐linear population dynamics into the analysis of clonogenic growth in vitro

Molecular Oncology, EarlyView.
Limiting dilution assays (LDAs) quantify clonogenic growth by seeding serial dilutions of cells and scoring wells for colony formation. The fraction of negative wells is plotted against cells seeded and analyzed using the non‐linear modeling of LDAcoop.
Nikko Brix, Daniel Samaga, Katharina Gehr, Benedek Dankó, Mohamed Schumann, Guido Drexler, Ahmed Alnatsha, Georg Beyer, Ujjwal Mahajan, Martin Selmansberger, Julia Mayerle, Claus Belka, Horst Zitzelsberger, Kirsten Lauber   +13 more
wiley   +1 more source

Assessment of gene signatures following the inhibition of IL-23: a study to evaluate the mechanistic effects behind the clinical efficacy of guselkumab in patients with psoriatic arthritis. [PDF]

Front Immunol
Mastrangelo M, Ruscitti P, Bruni M, Lucantonio E, De Berardinis A, Barile A, Fargnoli MC, Cipriani P, Esposito M, Pellegrini C.   +9 more
europepmc   +1 more source

Plecstatin inhibits hepatocellular carcinoma tumorigenesis and invasion through cytolinker plectin

Molecular Oncology, EarlyView.
The ruthenium‐based metallodrug plecstatin exerts its anticancer effect in hepatocellular carcinoma (HCC) primarily through selective targeting of plectin. By disrupting plectin‐mediated cytoskeletal organization, plecstatin inhibits anchorage‐dependent growth, cell polarization, and tumor cell dissemination.
Zuzana Outla, Jan Kosla, Magdalena Prechova, Lukas Frick, Patricia Bortel, Yasmin Borutzki, Andrea Bileck, Christopher Gerner, Samuel M. Meier‐Menches, Selma Osmanagic‐Myers, Martin Gregor   +10 more
wiley   +1 more source

New aspects on the Il Khans international conference in Ulaan Baatar, Mongolia, 21-23 May 2014

, 2014
Judith Kolbas
openalex   +1 more source

Correction for Ota et al., Engineering a protease-stable, oral single-domain antibody to inhibit IL-23 signaling. [PDF]

Proc Natl Acad Sci U S A
europepmc   +1 more source

Single-cell multiomics reveals macrophage-derived IL-23 and CXCL9/10 drive pathogenic IFNG⁺IL17⁺ T cells in immunotherapy-related colitis. [PDF]

J Immunother Cancer
Tang Z, Shi J, Xu S, Liu S, Yin W, Xiang Y, Li J, He Z, Yao X, Li Z, Xiao R, Deng H.   +11 more
europepmc   +1 more source

Circulating MicroRNAs in Patients with Psoriasis Treated with Anti-IL-23: A Cohort Study. [PDF]

Dermatol Ther (Heidelb)
Diotallevi F, Matacchione G, Campanati A, Marinelli Busilacchi E, Viola N, Pace I, Fontana B, Roncarati R, Bonafè M, Ferracin M, Sabbatinelli J, Olivieri F.   +11 more
europepmc   +1 more source

Clinical insights into IL-23 inhibition: risankizumab for Crohn's disease through a systematic review and meta-analysis of randomized controlled trials. [PDF]

Therap Adv Gastroenterol
Huang PF, Huang TY, Cheng YC, Chen PJ, Chang WK, Chang CF.   +5 more
europepmc   +1 more source

Th17、Treg、IL-23和IL-17对强直性脊柱炎发病发展过程的影响

, 2017
董海德
openalex   +1 more source